Physician profile
Thomas Wayne Lewis
NPI 1841268323
$741.67
in general payments reported to CMS, 2019-2025
12 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $184 · 2021: $13.71 · 2022: $131 · 2023: $137 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $309.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $247.85 | 2020-2023 | |
| Phathom Pharmaceuticals, INC. | $123.69 | 2025 | Voquezna |
| Astellas Pharma US INC | $74.99 | 2019 | |
| Glaxosmithkline, LLC. | $70.07 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $53.45 | 2022-2023 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $52.30 | 2022-2023 | |
| Amarin Pharma, INC. | $29.59 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.22 | 2023 | |
| Abbott Laboratories | $22.18 | 2022 | |
| Kerecis Limited | $15.63 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Dexcom, INC. | $14.61 | 2023 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $13.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.